Emerging Roles of Aryl Hydrocarbon Receptors in the Altered Clearance of Drugs during Chronic Kidney Disease

Santana Machado, Tacy; Cerini, Claire; Burtey, Stéphane

doi:10.3390/toxins11040209

Open AccessReview

Emerging Roles of Aryl Hydrocarbon Receptors in the Altered Clearance of Drugs during Chronic Kidney Disease

by

Tacy Santana Machado

^1,2,

Claire Cerini

^2,* and

Stéphane Burtey

^2,3,4

¹

CAPES Foundation, Ministry of Education of Brazil, Brasília DF 70040-020, Brazil

²

Aix Marseille Université, INSERM, C2VN, 13005 Marseille, France

³

APHM, Conception Hospital, Centre de Néphrologie et Transplantation Rénale, 13005 Marseille, France

⁴

European Uraemic Toxin Working Group of ESAO, endorsed by ERA-EDTA [EUTox], 3500 Krems, Austria

^*

Author to whom correspondence should be addressed.

Toxins 2019, 11(4), 209; https://doi.org/10.3390/toxins11040209

Submission received: 15 February 2019 / Revised: 12 March 2019 / Accepted: 3 April 2019 / Published: 7 April 2019

(This article belongs to the Special Issue Disposition of Uremic Toxins: The Challenges in Uremia)

Download

Browse Figure

Versions Notes

Abstract

Chronic kidney disease (CKD) is a major public health problem, since 300,000,000 people in the world display a glomerular filtration rate (GFR) below 60 mL/min/1.73m². Patients with CKD have high rates of complications and comorbidities. Thus, they require the prescription of numerous medications, making the management of patients very complex. The prescription of numerous drugs associated with an altered renal- and non-renal clearance makes dose adjustment challenging in these patients, with frequent drug-related adverse events. However, the mechanisms involved in this abnormal drug clearance during CKD are not still well identified. We propose here that the transcription factor, aryl hydrocarbon receptor, which is the cellular receptor for indolic uremic toxins, could worsen the metabolism and the excretion of drugs in CKD patients.

Keywords: AhR; uremic toxins; drug clearance

Share and Cite

MDPI and ACS Style

Santana Machado, T.; Cerini, C.; Burtey, S. Emerging Roles of Aryl Hydrocarbon Receptors in the Altered Clearance of Drugs during Chronic Kidney Disease. Toxins 2019, 11, 209. https://doi.org/10.3390/toxins11040209

AMA Style

Santana Machado T, Cerini C, Burtey S. Emerging Roles of Aryl Hydrocarbon Receptors in the Altered Clearance of Drugs during Chronic Kidney Disease. Toxins. 2019; 11(4):209. https://doi.org/10.3390/toxins11040209

Chicago/Turabian Style

Santana Machado, Tacy, Claire Cerini, and Stéphane Burtey. 2019. "Emerging Roles of Aryl Hydrocarbon Receptors in the Altered Clearance of Drugs during Chronic Kidney Disease" Toxins 11, no. 4: 209. https://doi.org/10.3390/toxins11040209

APA Style

Santana Machado, T., Cerini, C., & Burtey, S. (2019). Emerging Roles of Aryl Hydrocarbon Receptors in the Altered Clearance of Drugs during Chronic Kidney Disease. Toxins, 11(4), 209. https://doi.org/10.3390/toxins11040209

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Menu

Emerging Roles of Aryl Hydrocarbon Receptors in the Altered Clearance of Drugs during Chronic Kidney Disease

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Further Information

Guidelines

MDPI Initiatives

Follow MDPI